Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis Launches Global Lupus Nephritis Trials Network
When lupus goes on the attack, the kidneys are its most common target. Nearly two out of three people with lupus have kidney damage (called lupus nephritis). That’s why top experts in this field came together at an all-day conference hosted by the LRI. The conference launched a new international alliance of researchers specializing in lupus nephritis – the Lupus Nephritis Trials Network (LNTN).
Attendees focused on two critical questions: 1) Which new medicines have the greatest potential to treat lupus nephritis; 2) How should these medications be tested in clinical trials?
LRI Partners with LNTN for New Lupus Treatments
The conference is a part of an ongoing partnership between the LNTN and the LRI. LNTN unites over 100 academic investigators from around the world to conduct clinical trials in lupus nephritis and to simplify the process of testing new drugs by developing standardized clinical trial methods. The Network has already secured U.S. government and European Union funding for three trials of new approaches to the treatment of lupus nephritis.
“We are grateful to the LRI for being a founding supporter of LNTN and for sponsoring this meeting, a first in the field of lupus nephritis,” noted Betty Diamond, MD, Center for Autoimmune and Musculoskeletal Diseases at The Feinstein Institute for Medical Research. “Concentrating on highly innovative approaches, the Network is addressing a real need for safer and more effective treatments.”
“This conference demonstrates how breakthrough discoveries the LRI funded in lupus nephritis are informing the development of new treatments and accelerating clinical trials,” commented Margaret Dowd, President and CEO of the Lupus Research Institute.